Reduced incidence of laryngospasm with remifentanil-midazolam anaesthesia compared to halothane-fentanyl.
OBJECTIVE
To compare the incidence of laryngospasm by using halothane-fentanyl anaesthesia and midazolam-remifentanil anaesthesia in paediatric patients undergoing eye surgery.


METHODS
We enrolled 120 ASA physical status I children aged 7-12 years scheduled for eye surgery from March 2004 to February 2006 in this prospective clinical trial study. Children suffering from any medical condition that could affect airway reflexes such as active upper respiratory infection, symptomatic asthma, obesity, patients with predicted difficulty in tracheal intubation were not included in the study. Patients with prolonged or difficult intubation or those who received another drug before extubation were excluded from the study. Using a random numbers table, participants were allocated to two equal groups. After induction of anaesthesia, in one group Halothane 1% was administered for the maintenance of anaesthesia in addition with intravenous fentanyl 1.5 microg kg(-1), and for the patients of the other group midazolam with a dose of 0.1 mg kg(-1) and remifentanil infusion by a dose of 0.1 microg kg(-1) min(-1) was administered. The patients were extubated in a unique plan of anaesthesia, using the sign of swallowing as a clinical indicator for extubation of patients.


RESULTS
The incidence of laryngospasm was lower in midazolam-remifentanil group (0%) in comparison with halothane-fentanyl group (6.6%).


CONCLUSIONS
The results of our study suggest that remifentanil combined with midazolam in children undergoing eye surgery provided a better condition for extubation of the patients.
Ali
Shahriari
S
Department of Anesthesiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
D000768:Anesthesia, General; D018685:Anesthetics, Inhalation / Q000009:adverse effects* / Q000627:therapeutic use; D018686:Anesthetics, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005283:Fentanyl / Q000009:adverse effects* / Q000627:therapeutic use; D006221:Halothane / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007826:Laryngismus / Q000517:prevention & control*; D008874:Midazolam / Q000009:adverse effects* / Q000627:therapeutic use; D013508:Ophthalmologic Surgical Procedures; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D011183:Postoperative Complications; D011184:Postoperative Period; D000077208:Remifentanil; D012307:Risk Factors
D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous; D010880:Piperidines; D000077208:Remifentanil; D008874:Midazolam; D005283:Fentanyl; D006221:Halothane